Namodenoson Shows Promising Survival in Advanced Pancreatic Cancer Trial

Clinical Trails /

Updated results from a Phase 2a clinical trial suggest that namodenoson (CF102), an oral A3 adenosine receptor agonist, may provide lasting disease control for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have already received multiple rounds of treatment. The study met its main safety goal, with no new safety concerns reported in patients receiving […]

Namodenoson Shows Promising Survival in Advanced Pancreatic Cancer Trial Read More »

FDA Approves Belzutifan Plus Pembrolizumab for High-Risk Kidney Cancer After Surgery

Drug Approvals /

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with high-risk clear cell renal cell carcinoma (ccRCC) after surgery, establishing a new standard of care. The approval is based on the phase 3 LITESPARK-022 trial, which showed the combination reduced the risk of cancer recurrence or death

FDA Approves Belzutifan Plus Pembrolizumab for High-Risk Kidney Cancer After Surgery Read More »

Blood Protein Test Shows Promise for Early Detection of Pancreatic Cancer

Research Advances /

Researchers have identified a blood protein signature that may help detect pancreatic ductal adenocarcinoma (PDAC) in people with new-onset diabetes, potentially allowing the cancer to be found at an earlier, more treatable stage. Using a low-cost blood test based on MALDI-TOF mass spectrometry and a machine learning model, the researchers achieved 85% accuracy in distinguishing diabetes caused by

Blood Protein Test Shows Promise for Early Detection of Pancreatic Cancer Read More »

Immunotherapy Remains Standard First-Line Treatment for HER2-Negative Metastatic Gastric Cancer

Immunotherapy /

Experts say that combining an immune checkpoint inhibitor with chemotherapy is the standard first-line treatment for patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) cancer. Because many patients receive only one line of therapy, choosing the best initial treatment based on biomarkers is important. In a case discussion, a 60-year-old man with stage IV

Immunotherapy Remains Standard First-Line Treatment for HER2-Negative Metastatic Gastric Cancer Read More »

Zanubrutinib Plus Rituximab Improves Survival in First-Line Mantle Cell Lymphoma Trial

Treatment /

The phase 3 MANGROVE trial showed that a chemotherapy-free combination of zanubrutinib (Brukinsa) and rituximab (Rituxan) significantly improved progression-free survival compared with standard chemoimmunotherapy as a first-line treatment for mantle cell lymphoma (MCL). The combination reduced the risk of disease progression or death by 43%. Overall survival data are still early but currently favor the zanubrutinib group.

Zanubrutinib Plus Rituximab Improves Survival in First-Line Mantle Cell Lymphoma Trial Read More »

Mayo Clinic Study Reveals Early T-Cell Programming That Could Improve Cancer Immunotherapy

Research Advances /

Researchers at the Mayo Clinic have discovered that the body’s cancer-fighting CD8-positive T cells begin preparing for their immune role much earlier than previously believed. Instead of developing these abilities only after leaving the thymus, the cells start this process while still maturing inside the thymus. The study also found that the PD-1 protein acts as an important

Mayo Clinic Study Reveals Early T-Cell Programming That Could Improve Cancer Immunotherapy Read More »

Annamycin Plus HiDAC Shows Higher Remission Rates in Interim MIRACLE AML Trial

Treatment /

The first planned interim analysis of the phase 2/3 MIRACLE trial showed that adding liposomal annamycin to high-dose cytarabine (HiDAC) produced higher remission rates than HiDAC alone in patients with relapsed or refractory acute myeloid leukemia (AML). After one treatment cycle, complete remission rates were 43% with the 190 mg/m² annamycin dose and 36% with the 230 mg/m² dose,

Annamycin Plus HiDAC Shows Higher Remission Rates in Interim MIRACLE AML Trial Read More »

Epcoritamab Plus Lenalidomide Improves Progression-Free Survival in Phase 3 DLBCL Trial

Treatment /

The phase 3 EPCORE DLBCL-4 trial found that a chemotherapy-free combination of epcoritamab (Epkinly) and lenalidomide (Revlimid) significantly improved progression-free survival compared with R-GemOx chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The treatment reduced the risk of disease progression or death by 56%–60%, depending on the analysis. No new safety concerns were identified,

Epcoritamab Plus Lenalidomide Improves Progression-Free Survival in Phase 3 DLBCL Trial Read More »

EU Approves Enhertu for HER2-Positive Solid Tumors Regardless of Cancer Type

Drug Approvals /

The European Union has approved trastuzumab deruxtecan (Enhertu) as a single treatment for adults with advanced or metastatic HER2-positive (IHC 3+) solid tumors. The approval covers patients whose cancer has progressed after previous treatments and who have no satisfactory treatment options. Because it is a tumor-agnostic approval, the drug can be used regardless of where the cancer started

EU Approves Enhertu for HER2-Positive Solid Tumors Regardless of Cancer Type Read More »

AI Designs Custom Proteins to Improve Drug Delivery and Safety

Precision Medicine /

Researchers have developed a new AI tool called neural iterative selection-expansion (NISE) that designs proteins to bind specific drugs. Unlike traditional methods that rely on lengthy laboratory testing, NISE uses an AI-guided design process to quickly predict and improve protein-drug interactions. In early experiments, nearly all of the AI-designed proteins successfully bound to their target

AI Designs Custom Proteins to Improve Drug Delivery and Safety Read More »